Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
Mike Gladstone
Advertisement
Articles by Mike Gladstone
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
AMCP Nexus 2026 preview: PBM reform rollout and drug pricing policy top the agenda
2
Payers keep coming back to pre-approval evidence long after it's posted | AMCP Nexus 2026
3
5 things you should know about intismeran, the Moderna-Merck cancer vaccine
4
Christine Johnston on biosimilar interchangeability and PBM formularies
5